Finally, the signature derived from cluster2 KLRC1+ KLRK1+TRM CD28− (Fig. 7D,F and Table S4), likely characterized by a TRM phenotype and expressed in both NT and tumor site (C2 KLRC1+ KLRK1+TRM CD28− /Adaptive immunity) and including KLRC1, CD8A, CD8B, CD3E, KLRK1, was not significantly prognostic in all patient subgroups in the LUAD TCGA dataset (Fig. 8E). This evidence concerns the gene CD28 and neoplasm.